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Abstract 
Continuous simulation mathematical models are proposed for two different epidemic situations: Hepatitis 
B in a cohort of newborns followed for life, and one of the danger groups in the current AIDS epidemic. 
The paper describes the rational behind the systems of differential equations used to model both 
situations, and the way to test alternative policies, such as vaccination, preventive measures, or the effects 
of new drugs on AIDS.  
 
Introduction 
The use of mathematical models in Medicine goes back to Daniel Bernoulli, who in 1760 used a 
mathematical method to study techniques of protection against smallpox. In 1927, W.O.Kermack and 
A.G.McKendrick [1] used differential equations to understand a cholera epidemic. Since then, many 
authors have developed mathematical models of epidemics. With the emergence of AIDS, this discipline 
has had a renaissance.  
 
In this paper, we will model two different epidemics using differential equations: Hepatitis B among a 
cohort of the total population, and AIDS restricted to a homosexual population.  
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To build the models, we have made use of differential equations, based on a variation of the basic 
Kermack and McKendrick vaccination model, where the parameters can be viewed as the mathematical 
expectations of random variables subject to a Poisson distribution. The systems of differential equations 
we have developed have been solved numerically by means of the OOCSMP language, designed by the 
first author [2]. The associated simulation environment makes it possible to adjust the parameters of the 
models with many degrees of freedom. Its use makes it very easy to try and test different scenarios and 
"what if" situations.  
 
For Hepatitis B, we discuss different strategies of universal vaccination. The model is nonlinear and 
provides an estimate of the indirect effect of vaccination. It is a standard vaccination model, what is new is 
the way in which it displays clearly the herd immunity effect: the fact that vaccination also protects 
unvaccinated individuals in an indirect way, because of the smaller number of candidates to spread 
infection [3]. To validate the model we have used data obtained from studies of prevalence of Hepatitis B 
markers [4].  
 
In the case of AIDS [5] [6] we have built a similar model adjusted to the real data, that shows the effect of 
behavioral prevention and predicts the effect of the new anti-AIDS drugs introduced in 1997, our main 
contribution to the field, compared to previous models of the same disease [7] [8]. Two factors are 
considered: the maximum effect of the treatment, and the rate of its spread. In this case, no validation is 
possible, since real data are not yet available, but the model can be used for prediction purposes [include 
here a note about validation by real data published after the paper was written].  
 
Building the basic model. 
Since Kermack and McKendrick established their well-known mathematical model [1] for a Cholera 
epidemic, the model has been used in many other situations [3]. We have used this model as starting point, 
therefore it is summarily explained in this section. However, we have introduced several enhancements to 
take in consideration the special cases of Hepatitis-B and AIDS epidemics. 
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In some epidemics, a closed population may be classified into three different disjoint subsets: Susceptible 
(S), Infectious (I), and Resistant (R). The applicable model consists of the following equations:  
 
  dS/dt = - r(t) S(t)I(t) 
  dI/dt =   r(t) S(t)I(t)  - ß I(t) 
  dR/dt =   ß I(t) 
  
The coefficient r(t) is a measure of the proportion of new infections arising from meetings between 
susceptible and infectious. This coefficient is unknown and must be estimated if the model is to describe 
the epidemic. In general, it is a function of time (t) and is affected by medical prevention measures, social 
behavior and the virulence of the infection.  
 
The β coefficient is the proportion of infectious people that pass to the Resistant class every unit of time. 
This coefficient can be also viewed as the inverse of the mean of a random variable X with a Poisson 
distribution, that represents the time needed for an infectious person to pass to the Resistant class. Observe 
that, as the mathematical expectation of X is 1/β, the probability of staying in the infectious class after 
time t, assuming that a person has been infected at t=0, is:  
 P(X>t) = exp(-ß t) 
Therefore, the number of infectious people after time t, for an initial number I(0), will be:  
 I(t) = I(0)  exp (-ß t) + ∫[0-t]  r(x)S(x)I(x)exp(-ß (t-x))dx 
We derivate this expresion with respect to t, and get:  
 dI/dt = -ß I(0) exp(-ßt) + r(t)S(t)I(t) exp(-ßt) -ß exp(-ßt) ∫[0-t]  r(x)S(x)I(x)exp(-ßx)dx = -ß I(t) + r(t)S(t)I(t) 
i.e. the second equation in the Kermack-McKendrick model.  
 
Simulation of a Hepatitis B epidemic in Spain 
The Hepatitis B virus (HBV) infects people everywhere in the world. In general, the outcome of HBV 
infection depends on the immune response of the individual. An adequate immune response will lead to 
the production of antibodies that clear the infection and give lifelong immunity. An inadequate immune 
response allows continued viral replication; if maintained for six months or longer, such viral production 
usually persists indefinitely, and the infected individual becomes an asymptomatic carrier of infection. 
Such carriers are at risk to develop different diseases later in life and can transmit HBV infection. 
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Transmission itself is via blood or blood products, and can occur during sexual intercourse, or in the 
sharing of needles by drug abusers.  
 
Infection by HBV is a major public health concern in Spain. 60000 new infections are estimated to occur 
every year, although only about 20% are symptomatic [9].  There is serological evidence of previous 
contact with the virus in at least 20% of the adult population. Moreover, about half a million people are 
chronic virus carriers, the prevalence being especially high in young adults. The seroepidemiological 
surveys conducted in special collectives and in the general population indicate, in our environment, an 
epidemiological pattern of intermediate endemicity, similar to that of other Mediterranean countries.  
 
Vaccination is the main method currently available to reduce the morbidity associated with HBV. In 1986, 
a new Hepatitis B vaccine was obtained by genetic engineering. Its efficacy (85-95%) [10] is identical to 
that of the previous vaccine derived from human plasma, and its side-effects and adverse reactions are 
mild or benign.  
 
The aim of this section is to discuss different strategies of vaccination, such as universal immunization of 
teenagers and/or newborns. We first describe the natural history of Hepatitis B and deduce the appropriate 
equations. As population, we will consider a cohort of newborns to be followed for life, which is divided 
into several classes:  
 
• Susceptible (X), containing those people who have had no contact with the virus.  
• Subclinic infected (Is), those who have had contact with the virus, but don't need medical assistance. 
• Clinic infected (Ic), those who do need that assistance.  
• Carriers of low replication (Pb), defined by the presence of the viral marker HBsAg and the absence of 
virus DNA.  
• Carriers of high replication (Pa), defined by the presence of the two markers HBsAg, HBeAg and virus 
DNA.  
• Immunes (Im) defined as the class of subjects who had in the past contact with the virus and got so 
many antibodies that they cannot be infected. This class also includes successfully vaccinated people.  
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• Dead from Hepatitis B (DHB). This groups includes those who die during the infection phase, plus 
those who become high replication carriers and die at that stage. We assume that the second cause 
starts taking effect at about 30 years of age.  
 
The following set of equations can be used to describe the course of the illness:  
 dX/dt  = -λ(t).X.(Is/4+Ic/8+Pb+Pa/4) 
 dIs/dt = 0.8 λ(t).X.(Is/4+Ic/8+Pb+Pa/4) - 2Is 
 dIc/dt = 0.2 λ(t).X.(Is/4+Ic/8+Pb+Pa/4) - 2Ic 
 dPb/dt = 0.075 (2Is+2Ic) + 0.1Pa - 0.02Pb 
 dPa/dt = 0.025 (2Is+2Ic) + 0.01Pb - 0.1Pa - 0.05K[30...)Pa 
 dIm/dt = 0.9 (2Is+2Ic) +0.02Pb 
 dDHB/dt= 0.001Ic + 0.05K[30...)Pa 
where K[30...) is zero for time less than 30 years and one otherwise, representing the Hepatitis B mortality 
in the class of high replication carriers. More details about the medical data can be found in references [4], 
[11] and [12]. Table 1 summarizes those data for Catalonia (Spain).  
 
     Age(years)      Carriers(%)     Immune(%)  
         6-11           0.2              1.5   
        13-14           0.8              1.7   
        15-24           1.2              9.3    
        25-44           2.4             16.7   
        45-64           1.9             19.9   
          >64           -               23.2   
Table 1: Data on Hepatitis B in Catalonia (Spain.) The age groups are 
heterogeneous because they represent age states (infancy, adolescent, 
teenagers...) The Carriers column represents the sum of both types of carriers 
(Pa+Pb.)  
 
The mathematical model has been translated into the OOCSMP language, an object-oriented extension to 
the old CSMP III language on which we have been working for some time [2]. The OOCSMP compiler 
automatically generates C++ or JAVA code that includes a graphic simulation environment that makes it 
very easy to test different alternatives, to refine the values of the parameters, and to obtain the most 
appropriate approximation for the behavior of the affected populations, compatible with the existent data.  
 
To make the results of the simulation runs agree with the data, we had to approximate a function that gives 
the number of infecting encounters between susceptible and infected people, which is not known directly. 
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We decided to define a reasonable piecewise function λ(t) and use parameter approximation techniques to 
fix the turning points. The best approximation was attained with the following set of points: [(0,1), (11,1), 
(22,3), (35,0.3), (120, 0.3)], which correspond to a constant danger for children, a linearly growing danger 
for teenagers (reaching a triple rate of infection at age 22), a progressively smaller danger for young adults 
until 35, and a later stabilization at a risk 30 per cent of the initial risk for children. This adjustment looks 
reasonable in theory and similar to what can be expected from people behavior: transmission takes place 
mainly through sexual contacts and among drug-abusers, thus we can expect the infection to grow for 
teenagers and young adults, and reach a minimum for individuals 35 or older. A few infections are also 
vertically transmitted by the mother at childbirth.  
 
This is a normal way to do parameter adjustments (different examples can be seen in [13].) It is possible 
to build an automatic parameter adjustment program that tries every combination of values of interest and 
compares the results to the data to be adjusted with some mathematical criterion, but in our case the 
number of parameters was small enough that the adjustment could be done by manual trial and error. 
Thus, the general shape of the piecewise function was derived theoretically, but the actual values at the 
turning points were manually adjusted to get the best fit. 
 
Figure 1 shows the number of infected people in three different situations: an unprotected population, a 
population where all the babies are vaccinated at birth, and a third where vaccination was delayed till age 
11. Roughly, in the case of no vaccination, the infected population corresponds to the derivative of the 
sum of both columns in table 1. It can easily be seen that this derivative reaches its maximum value at an 
age of about 25, in agreement with our results. It can also be seen that vaccination at 10 provides almost 
the same protection as vaccination at birth. 
 
Figure 2 shows the herd immunity effect (see [3] and the explanation of the effect at the introduction of 
this paper) by comparing the results of the simulation of two different vaccination campaigns. In the first, 
100% of the children are vaccinated at age 11, in the second only 80% of them. The figure shows the 
number of infected people in the cohort. It can be seen that the second option is almost as successful as 
the first, compared to the absence of vaccination (see figure 1), where the number of infected people is 
more than an order of magnitude larger. The fact that 80% of the population is vaccinated reduces the 
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probability of infection for unprotected people, and provides for a larger than proportional protection for 
the population as a whole.  
 
Simulation of AIDS evolution in a homosexual population 
AIDS is very similar to Hepatitis B in its way of transmission, which happens mainly through sexual 
contacts and sharing of needles among drug-abusers. We have tried to reproduce the evolution of AIDS 
among the homosexual risk group in Spain, using the data provided by the Spanish Ministry of Health 
[14], which represent the number of new AIDS positives diagnosed every year and is shown in table 2. 
When this paper has been written, the published data only reach to 1996. 
 
1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 
   1    1    4   11   37   87  207  338  508  586  687  778  779  878  927  739 
Table 2: Historical data on AIDS cases among homosexuals in Spain. The numbers 
correspond to people diagnosed with symptomatic AIDS, corresponding to 
variable A in our model. 
 
The population under consideration may be divided into the following sections:  
• Susceptible (S), containing those people in the population who have had no contact with the virus. 
This section increases through natural population growth (PN) and decreases by contagion (DS), going 
to the next two sections.  
• Carriers without development (CN), for those who have had contact with the virus but never develop 
AIDS. Medical estimations [15] indicate that 8% of people subject to contagion may be immune and 
come into this group. The number of people in this group would decrease through deaths by other 
causes, which we have not considered, as this segment of the population is small and we are not 
interested in its evolution.  
• Carriers with development (CY), for those who have been infected with the HIV virus but have not 
developed AIDS symptoms, although they will develop AIDS, unless they receive a successful 
preventive treatment. About 92% of people subject to contagion would come into this group, 
according to the same medical estimations. After a certain stay in this state, the members of this group 
would go to the next section of the population (develop symptomatic AIDS.) 
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• AIDS sick people (A), for those members of the population who have developed fully symptomatic 
AIDS and exhibit specific clinical features, in opposition to both types of carriers, which are 
asymptomatic. This group receives new arrivals from the preceding section and loses members by 
death.  
• Dead because of AIDS (DA).  
 
We have used the following set of equations to describe the course of the illness:  
 dS/dt  = PN - DS 
 dCN/dt = 0.08 . DS 
 dCY/dt = 0.92 . DS - ADP3 . CY 
 dA/dt  = ADP3 . CY - DAP3 . A 
 dDA/dt = DAP3 . A 
where the following considerations have been taken into account:  
 
• PN (natural growth of the homosexual population) has been taken as a constant and estimated at 100 
per year.  
• DS (contagion) has been computed using the following formula:  
 DS = TASA . PREV . S . (CN + CY + K.A) 
where we assume that both carriers and sick people may transmit AIDS. However, most of the sick people 
will be under treatment and subject to special preventive measures, represented in the formula by constant 
K. In our simulations, we have set K to zero, indicating that contagion by AIDS sick people is negligible 
as compared to contagion by carriers.  
 
In the formula, TASA is a constant of proportionality, while PREV is a term we call the "prevention 
factor" that embodies the application of general preventive measures against AIDS contagion. This factor 
decreases as the prevention measures increase. These measures depend strongly on social behavior, were 
practically nonexistent during the first years of the AIDS epidemic, and are widely spread now, at least in 
the homosexual population. We have modeled this term by means of the following equation:  
 PREV = MIN (9, PV1 + (12-PV1) . EXP (-PV0 . TIME)) 
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Figure 3 shows the evolution of the prevention factor between 1980 and 1996. PV1 represents the 
minimum contagion rate attainable by current preventive measures. We have used a value about 100 times 
smaller than the maximum contagion rate. PV0 describes the speed of application of the preventive 
measures. Notice that the smallest the prevention factor, the less will AIDS be transmitted from carriers to 
susceptible persons.  
• ADP3 (rate of pass from carrier to sick) is a constant during most of the period under study, with a 
value of 0.1, which corresponds to an average of 10 years delay from contagion to the development of 
full AIDS. However, we have made this term time dependent, substituting for it a piecewise linear 
function that attains a better adjustment of the model during the first 10 years (1980-1990).  
• DAP3 (death rate for AIDS sick people) is a constant during most of the period under study, 
approximately inverse to the mean life expectancy.  
 
Additional magnitudes of interest are:  
  dAD/dt = ADP3 . CY 
  ADiag  = AD(TIME)-AD(TIME-1) 
where AD is the cumulative number of diagnosed AIDS carriers, and ADiag is the number of carriers 
diagnosed per year. This is the magnitude that we have used to validate the model, by comparing its 
results to the real data shown in table 2.  
 
Table 3 shows the results of a simulation of our model, where we have added the real data as an additional 
column.  
 
  YEAR         AD         DA         CY          A      ADiag    Real Data 
  1980          1          0          9          1          1 
  1981          2          0         31          1          1       1 
  1982          4          1        105          3          2       1 
  1983         11          2        291          9          7       4 
  1984         29          6        671         22         18      11 
  1985         71         16       1319         55         42      37 
  1986        165         40       2260        126         94      87 
  1987        345         91       3442        255        180     207 
  1988        646        188       4749        459        301     338 
  1989       1098        354       6030        745        452     508 
  1990       1718        611       7143       1107        620     586 
  1991       2474        978       8019       1496        756     687 
  1992       3306       1452       8660       1854        832     778 
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  1993       4193       2024       9066       2169        887     779 
  1994       5109       2678       9256       2431        916     878 
  1995       6037       3401       9263       2636        928     927 
  1996       6958       4174       9122       2784        921     739 
  1997       7859       4983       8866       2877        901 
  1998       8731       5811       8527       2920        872 
  1999       9566       6646       8132       2920        835 
  2000      10360       7477       7702       2884        795 
Table 3. Simulation of AIDS development among the Spanish homosexual population. Each column shows the 
results of the execution of the model for the corresponding variable, as described in the text. 
 
The last two columns in the table show a strong correlation. In fact, the last piece of real data (1996) is 
unreliable, due to delayed declaration of the illness, which means that the actual number for this year will 
not be known until some time in the future. Both the model and the real data show the number of new 
diagnosed cases reaching a maximum in 1995 and starting a slow descent, as a result of the use of 
preventive measures. The real data include changes in the definition for AIDS along time. These changes 
have not been considered in our model, which is tailored to the current definition, which may explain 
some of the detailed differences. For a discussion on the effects of a change of definition, see [16].  
 
To attain these results (which can be seen in graphical form in figure 4), we have adjusted several of the 
parameters in the model, mainly TASA, PV1, PV0 and A2D.  
 
Simulation of the effect of the new AIDS treatment 
Very recently, some new anti-AIDS drugs have been introduced with promising results. Although they are 
currently under experimentation, their effect, if used during the carrier phase, seems to be a longer 
duration of the contagion/sickness delay, while they apparently increase the life expectancy of AIDS sick 
people once the illness is fully declared. It is possible that the use of these drugs may "cure" some of the 
sick, taking them back to the carrier phase, but this is not fully established.  
 
Although there are no current statistical data on the effect of the drugs, which means that we cannot 
validate our simulations, we have included in our model the first two improvements mentioned, for 
prediction purposes. The longest contagion/sickness delay is represented by an adjustment to the ADP3 
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term. For time greater than 1996 (the new drugs were introduced in 1997), this term is replaced by the 
function:  
 1 / (10 + EMMed . (1 - EXP (EfTP . (MedD-TIME)))) 
where MedD corresponds to 1996, EMMed is the maximum increase (in years) of the stay expectancy in 
the carrier phase, and EfTP is a parameter that regulates the speed with which the new treatments will be 
adopted. For instance, for EMMed=10 and very large EfTP, the stay expectancy in the carrier phase 
would suddenly jump from 10 to 20 years in 1997, while for EfTP=0 the stay expectancy would remain at 
10 years. Intermediate values of EfTP correspond to a gradual increase from 10 to 20 years (see figure 5).  
 
In a similar way, the longest life expectancy of AIDS sick people can be represented by adjusting the 
DAP3 term, which, for time greater than 1996, is replaced by the function:  
 1 / (A2D + EMMed1 . (1 - EXP (EfTP1 . (MedD-TIME)))) 
where EMMed1 is the maximum increase (in years) of the life expectancy of AIDS sick people, and 
EfTP1 regulates the speed with which the new treatments will be adopted. A2D is the expectancy constant 
prior to the introduction of the new drugs.  
 
With this modification, the results of our simulation for the last four years (1997-2000) become those in 
table 4 (see them also in graphical form in figure 6).  At the time this paper is written, there are no real 
data for these years, therefore our results are a prediction. Figure 7 shows a graphic comparison between 
predicted and real data for new AIDS diagnostics. 
 
YEAR       AD         DA          CY           A      ADiag 
  1997       7653       4742       9077       2910        695 
  1998       8171       5150       9110       3022        518 
  1999       8648       5531       9107       3118        477 
  2000       9110       5909       9053       3201        462 
Table 4. Simulation of the effect of the new anti-AIDS drugs. This table replaces the last four columns in table 3 
when the predicted effect of the new drugs is introduced in the model. The drugs were used since 1996, and their 
effect could not be tested until 1997. 
 
Comparing both series of results, we can estimate the expected effect of the use of the drugs:  
• The decrease on the number of new diagnosed cases will accelerate substantially.  
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• The number of deaths per year will decrease.  
• The number of carriers will increase initially, due to the longer stay of infected people in this phase 
and the increase of infection due to the larger number of carriers.  
• The number of AIDS sick people will also increase, due to their longer life expectancy.  
 
Other scenarios may be tested quite easily using the OOCSMP simulation environment. For instance, we 
can adjust the model to the real data as soon as they are available, by changing the values of the EMMed, 
EfTP, EMMed1 and EfTP1 parameters.  
 
Conclusions 
The use of a set of differential equations has proved useful to model the development of different 
epidemics and to test the effects of different policies for prevention and treatment. Continuous simulation 
is a powerful tool that can be used to compare alternatives and estimate their costs and effectiveness.  
 
The procedure has been applied to two very different situations: endemic Hepatitis B in a very special 
population (a cohort) and AIDS in a real situation (the homosexual danger group). In the first case, the 
effects of different vaccination campaigns has been simulated, with a clear demonstration of the herd 
immunity effect. In the latter case, a good correlation with real data has been attained. The model was 
easily extended to estimate the possible effects of the recently discovered drugs against AIDS.  
 
The simulation environment we have used (the OOCSMP language and compiler) has proved very 
appropriate and flexible for validation and parameter adjustment.  
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Figure 1: Three different strategies for Hepatitis B vaccination 
 
 
 
 
 
Figure 2: The herd effect in Hepatitis B vaccination 
 
 
 15
 
 
Figure 3: Evolution of the effect of AIDS prevention on homosexuals 
 
 
 
 
 
Figure 4: Simulation of the AIDS epidemic among homosexuals 
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Figure 5: Estimated effect of the new drugs on AIDS 
 
 
 
 
Figure 6: Prediction of the effect of the new drugs on AIDS 
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Figure 7: New AIDS diagnosed cases (simulation results vs. real data) 
 
